Olympus Diagnostic Systems has earned FDA clearance for its C-reactive protein (CRP) latex assay as an independent cardiac risk marker.
Olympus Diagnostic Systems has earned FDA clearance for its C-reactive protein (CRP) latex assay as an independent cardiac risk marker.
High sensitive (cardiac) application measurements, when used in conjunction with traditional clinical laboratory evaluations, may be useful as an independent marker of prognosis for recurrent events in patients with either stable coronary disease or acute coronary syndromes.
C-reactive protein is one of the most sensitive acute-phase reactants, say Olympus.
Measurement of CRP can have a role in the detection and evaluation of infection, tissue injury, inflammatory disorders and associated diseases.
The Olympus CRP latex assay offers three applications covering a variety of measuring ranges to quantify C-reactive protein in human serum.
The ranges include normal (5-170mg/L); sensitive (cardiac) (0.5-20mg/L); and highly sensitive (neonatal) (0.05-2.00mg/L).
The Olympus CRP latex assay is designed for use on the company's chemistry-immuno analysers, including the AU400/400e, AU600, AU640/640e, AU2700 and AU5400.
